In Segment A, participants will obtain distinctive doses and schedules of oral ABBV-744 tablet to discover safe dosing regimen. More participants is going to be enrolled at the determined monotherapy dosign program. In Phase B, participants will receive oral ruxolitinib and ABBV-744 is going to be given as "include-on" therapy. https://abbv-744-therapeutic-pote58024.bloggactivo.com/31447992/details-fiction-and-clinical-trial-recruitment-for-abbv-744-study